NIH R01 · 2024
Development of a B Cell Therapeutic
Autoimmunity occurs due to a breakdown in immunological tolerance, leading to uncontrolled adaptive immune responses against self-tissues. There are an estimated 50 million Americans that suffer from autoimmunity, which encompasses 100+ different disorders, which collectively effect virtually every organ and tissue. With ~16% of the US population suffering from autoimmunity, in 2001, annual estimated costs for their treatment calculated were greater than $100 billion. While every autoimmune disease is associated with immune dysregulation, no universal treatments exist. This proposal aims to generate a novel, cost-effective, universal off-the-shelf adoptive cell therapy (ACT) that can be…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.